Total deletion of in vivo telomere elongation capacity: an ambitious but possibly ultimate cure for all age-related human cancers.
Authors
De Grey, Aubrey D N JCampbell, F Charles
Dokal, Inderjeet
Fairbairn, Leslie J
Graham, Gerry J
Jahoda, Colin A B
Porterg, Andrew C G
Affiliation
Department of Genetics, University of Cambridge, Downing Street, Cambridge CB2 3EH, UK. ag24@gen.cam.ac.ukIssue Date
2004-06
Metadata
Show full item recordAbstract
Despite enormous effort, progress in reducing mortality from cancer remains modest. Can a true cancer "cure" ever be developed, given the vast versatility that tumors derive from their genomic instability? Here we consider the efficacy, feasibility, and safety of a therapy that, unlike any available or in development, could never be escaped by spontaneous changes of gene expression: the total elimination from the body of all genetic potential for telomere elongation, combined with stem cell therapies administered about once a decade to maintain proliferative tissues despite this handicap. We term this therapy WILT, for whole-body interdiction of lengthening of telomeres. We first argue that a whole-body gene-deletion approach, however bizarre it initially seems, is truly the only way to overcome the hypermutation that makes tumors so insidious. We then identify the key obstacles to developing such a therapy and conclude that, while some will probably be insurmountable for at least a decade, none is a clear-cut showstopper. Hence, given the absence of alternatives with comparable anticancer promise, we advocate working toward such a therapy.Citation
Total deletion of in vivo telomere elongation capacity: an ambitious but possibly ultimate cure for all age-related human cancers. 2004, 1019:147-70 Ann. N. Y. Acad. Sci.Journal
Annals of the New York Academy of SciencesDOI
10.1196/annals.1297.026PubMed ID
15247008Type
ArticleLanguage
enISSN
0077-8923ae974a485f413a2113503eed53cd6c53
10.1196/annals.1297.026